A preoperative marker panel for the prediction of residual tumor and the decision making for repeat transurethral resection

Some clinical and molecular markers could improve the accuracy of residual tumor prediction at reTUR. Such a marker panel may help to identify patients with non-muscle-invasive bladder cancer who have residual tumor after first TUR and who may therefore benefit from reTUR.